Question 1

What is McKesson's P/B ratio?

Accepted Answer

McKesson (MCK) P/B ratio is currently not available. A negative or zero P/B occurs when accumulated losses, large buybacks, or special dividends have driven shareholders' equity below zero. In that case P/B is reported as N/A and analysts use P/S or EV/EBITDA as substitutes.

Question 2

How is the P/B ratio calculated?

Accepted Answer

P/B = Market Capitalisation ÷ Book Value of Equity (most recent quarterly shareholders' equity), or equivalently Share Price ÷ Book Value Per Share. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/B ratio?

Accepted Answer

The price-to-book (P/B) ratio compares a company's market capitalisation to its book value of equity (total shareholders' equity) on the most recent quarterly balance sheet. It is calculated as market cap ÷ book value of equity (equivalent to share price ÷ book value per share). A P/B below 1× implies the market values the business below its accounting net worth; values well above 1× reflect intangible assets, brand value, or a high return on equity.

Question 4

What is a good P/B ratio for McKesson?

Accepted Answer

A "good" P/B depends on the business model. Banks, insurers, and other capital-heavy financials typically trade near 1×; asset-light technology and consumer-brand companies can sustainably trade at 5×+ because much of their value is intangible. P/B is most informative when paired with return on equity (ROE). For McKesson specifically, the relevant sector benchmark is the current sector median of 3.2×.

Question 5

What is McKesson's historical P/B ratio range?

Accepted Answer

In the available daily series, McKesson (MCK) P/B ratio has ranged from a low of 1.4× in 2004 to a high of 6.6× in 2015.

Question 6

What was McKesson's P/B ratio in 2020?

Accepted Answer

McKesson (MCK) P/B ratio at the end of 2020 was 4.6×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month book value figure available at that date.

Question 7

Why does McKesson's P/B ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (book value). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.

Question 8

Why is McKesson's P/B ratio not available?

Accepted Answer

A negative or zero P/B occurs when accumulated losses, large buybacks, or special dividends have driven shareholders' equity below zero. In that case P/B is reported as N/A and analysts use P/S or EV/EBITDA as substitutes.


2026	$106B	-$2.17B	—	—	Mar 31, 2026
2025	$84.3B	-$2.07B	—	—	Mar 31, 2025
2024	$70.1B	-$1.97B	—	—	Mar 31, 2024
2023	$48.7B	-$1.86B	—	—	Mar 31, 2023
2022	$45.1B	-$2.27B	—	—	Mar 31, 2022
2021	$31B	-$21M	—	—	Mar 31, 2021
2020	$23.4B	$5.09B	4.6×	+1.8×	Mar 31, 2020
2019	$22.7B	$8.09B	2.8×	-0.1×	Mar 31, 2019
2018	$28.9B	$9.8B	2.9×	+0.1×	Mar 31, 2018
2017	$31.4B	$11.1B	2.8×	-1.2×	Mar 31, 2017
2016	$35.7B	$8.92B	4.0×	-2.6×	Mar 31, 2016
2015	$52.5B	$8B	6.6×	+1.8×	Mar 31, 2015
2014	$40.6B	$8.52B	4.8×	+1.3×	Mar 31, 2014
2013	$24.5B	$7.07B	3.5×	+0.4×	Mar 31, 2013
2012	$20.7B	$6.83B	3.0×	+0.3×	Mar 31, 2012
2011	$19.7B	$7.22B	2.7×	+0.4×	Mar 31, 2011
2010	$17.5B	$7.53B	2.3×	+0.8×	Mar 31, 2010
2009	$9.46B	$6.19B	1.5×	-0.8×	Mar 31, 2009
2008	$14.5B	$6.12B	2.4×	-0.4×	Mar 31, 2008
2007	$17.3B	$6.27B	2.8×	+0.1×	Mar 31, 2007
2006	$15.7B	$5.91B	2.7×	+0.5×	Mar 31, 2006
2005	$11.2B	$5.28B	2.1×	+0.4×	Mar 31, 2005
2004	$8.73B	$5.17B	1.7×	+0.1×	Mar 31, 2004
2003	$7.22B	$4.53B	1.6×	-1.1×	Mar 31, 2003
2002	$10.8B	$3.94B	2.7×	—	Mar 31, 2002


Charles River (CRL)	2.6×
Danaher (DHR)	2.6×
Spruce Biosciences (SPRB)	2.6×
Regeneron Pharmaceuticals (REGN)	2.6×
Henry Schein (HSIC)	2.5×
Labcorp Holdings (LH)	2.5×
Solventum (SOLV)	2.3×
Medtronic (MDT)	2.2×
Elevance Health (ELV)	1.9×
Becton, Dickinson and (BDX)	1.8×
Pfizer (PFE)	1.8×
Cigna (CI)	1.7×
Waters Corporation (WAT)	1.6×
Cooper Companies (COO)	1.5×
Universal Health Services (UHS)	1.5×
Biogen (BIIB)	1.4×
Baxter International (BAX)	1.4×
Zimmer Biomet Holdings (ZBH)	1.4×
Revvity (RVTY)	1.4×
CVS Health (CVS)	1.2×
Humana (HUM)	1.1×
Viatris (VTRS)	1.1×
Ovid Therapeutics (OVID)	0.8×
Centene (CNC)	0.8×
Teladoc Health (TDOC)	0.7×

P/B Ratio for McKesson (MCK) 2002-2026

P/B Ratio daily chart for McKesson (MCK)

Historical P/B Ratio for McKesson (MCK) from 2002 to 2026

About P/B Ratio at McKesson (MCK)

McKesson P/B Ratio by Year

McKesson P/B Ratio 2020: 4.6×

McKesson P/B Ratio 2019: 2.8×

McKesson P/B Ratio 2018: 2.9×

McKesson P/B Ratio 2017: 2.8×

McKesson P/B Ratio 2016: 4.0×

Sector peers by P/B Ratio — chart

Sector peers by P/B Ratio — table

Frequently asked questions

McKesson (MCK) Key Financials